Also listed under Hematologic Diseases
205 trials changed in the last 30 days: 14 stopped, 80 with notable changes, 111 with minor changes only.
Trial terminated
Also in this update: Primary completion date changed from estimate of Oct 31, 2030 to Oct 12, 2026; Final enrollment: 36 participants (planned 50)
M.D. Anderson Cancer CenterPhase 2 NCT04062266 Registry history of NCT04062266 on ClinicalTrials.gov (opens the registry)
Trial terminated
Also in this update: Trial sites reduced: 16 → 10 locations; Primary completion date changed from estimate of Feb 1, 2027 to Aug 28, 2026
Bristol-Myers SquibbPhase 1 NCT06419634 Registry history of NCT06419634 on ClinicalTrials.gov (opens the registry)
Trial terminated
Also in this update: Primary completion date changed from estimate of Dec 31, 2026 to Sep 16, 2026; Final enrollment: 52 participants (planned 120)
SystImmune Inc.Phase 1 NCT06714591 Registry history of NCT06714591 on ClinicalTrials.gov (opens the registry)
Trial terminated
Also in this update: Primary completion date changed from estimate of Dec 31, 2025 to Apr 21, 2026; Final enrollment: 49 participants (planned 124)
Maria Sklodowska-Curie National Research Institute of OncologyPhase 2 NCT04920968 Registry history of NCT04920968 on ClinicalTrials.gov (opens the registry)
Trial terminated
Also in this update: Primary completion date changed from estimate of Mar 2027 to Aug 31, 2026
AbbVieNot specified NCT05424562 Registry history of NCT05424562 on ClinicalTrials.gov (opens the registry)
Recruitment suspended
City of Hope Medical CenterPhase 1 NCT06195891 Registry history of NCT06195891 on ClinicalTrials.gov (opens the registry)
Trial terminated
Also in this update: Primary completion date changed from estimate of Dec 31, 2025 to Jan 10, 2024; Final enrollment: 12 participants (planned 21)
Centre Hospitalier Universitaire de Saint EtienneNot applicable NCT03439371 Registry history of NCT03439371 on ClinicalTrials.gov (opens the registry)
Trial status changed: Not Yet Recruiting → Suspended
M.D. Anderson Cancer CenterPhase 2 NCT07192237 Registry history of NCT07192237 on ClinicalTrials.gov (opens the registry)
Trial terminated
Also in this update: Primary completion date changed from estimate of Mar 31, 2027 to Aug 28, 2026; Final enrollment: 21 participants (planned 42)
Washington University School of MedicineEarly Phase 1 NCT06636175 Registry history of NCT06636175 on ClinicalTrials.gov (opens the registry)
Recruitment suspended
Also in this update: Primary completion pushed from Jul 8, 2026 to Jan 2027; Study completion pushed from Oct 31, 2027 to Jan 2029
Institut Paoli-CalmettesPhase 2 NCT06055621 Registry history of NCT06055621 on ClinicalTrials.gov (opens the registry)
Trial status changed: Not Yet Recruiting → Terminated
Also in this update: Primary completion date changed from estimate of Jul 31, 2026 to Aug 31, 2026; Final enrollment: 49 participants (planned 124)
Gadjah Mada UniversityPhase 4 NCT07320534 Registry history of NCT07320534 on ClinicalTrials.gov (opens the registry)
Recruitment suspended
University of WashingtonPhase 2 NCT06738368 Registry history of NCT06738368 on ClinicalTrials.gov (opens the registry)
Recruitment suspended
Huda SalmanPhase 1 NCT06071624 Registry history of NCT06071624 on ClinicalTrials.gov (opens the registry)
Recruitment suspended
Huda SalmanPhase 1 NCT06197672 Registry history of NCT06197672 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Mar 13, 2029 to Sep 27, 2029
And 1 more change in the last 30 days
CSL BehringPhase 3 NCT07648264 Registry history of NCT07648264 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from May 2026 to Jan 2027
Polaris GroupPhase 1 NCT05001828 Registry history of NCT05001828 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Oct 15, 2026 to Apr 15, 2027
Also in this update: Enrollment increased: 137 → 193 participants
AstraZenecaNot specified NCT05645172 Registry history of NCT05645172 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Mar 1, 2027 to Nov 1, 2027
Also in this update: Study completion pushed from Aug 2027 to Apr 1, 2028
Alliance for Clinical Trials in OncologyPhase 3 NCT03150693 Registry history of NCT03150693 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Oct 24, 2026 to Oct 24, 2027
National Cancer Institute (NCI)Phase 1 NCT03816319 Registry history of NCT03816319 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Dec 5, 2028 to Mar 6, 2031
Also in this update: Study completion pushed from Jun 18, 2030 to Sep 16, 2032
AmgenPhase 1/2 NCT07134088 Registry history of NCT07134088 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Start date pushed from Jun 30, 2021 to Jul 22, 2021; Study completion date changed from estimate of Nov 2026 to Sep 30, 2026
CareDxNot specified NCT04635384 Registry history of NCT04635384 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
TScan Therapeutics, Inc.Phase 3 NCT07702578 Registry history of NCT07702578 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Final enrollment: 539 participants (planned 700)
Janssen Research & Development, LLCPhase 3 NCT01804686 Registry history of NCT01804686 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Study completion date changed from estimate of Mar 31, 2027 to Jul 29, 2026
Astellas Pharma IncPhase 3 NCT03182244 Registry history of NCT03182244 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Study completion date changed from estimate of Jun 2026 to Sep 30, 2025
GCP-Service International West GmbHPhase 2 NCT05583552 Registry history of NCT05583552 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Study completion pushed from Jul 31, 2026 to Dec 31, 2026; Primary completion date changed from estimate of Mar 17, 2026 to Oct 10, 2025
Eric Stephen Winer, MDPhase 1 NCT05703542 Registry history of NCT05703542 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Apr 28, 2028 to Oct 11, 2028
Also in this update: Study completion pushed from Jul 3, 2028 to Jul 18, 2029
AstraZenecaPhase 1/2 NCT07109219 Registry history of NCT07109219 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
TScan Therapeutics, Inc.Phase 1 NCT05473910 Registry history of NCT05473910 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Ono Pharmaceutical Co., Ltd.Phase 1 NCT06547528 Registry history of NCT06547528 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Study completion moved earlier from Nov 21, 2028 to Feb 9, 2028; Final enrollment: 85 participants (planned 155)
Janssen Research & Development, LLCPhase 1 NCT06651229 Registry history of NCT06651229 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Primary completion date changed from estimate of Sep 29, 2026 to Jul 21, 2026; Final enrollment: 6 participants (planned 10)
Janssen Research & Development, LLCPhase 1 NCT07295951 Registry history of NCT07295951 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Primary completion date changed from estimate of Apr 2026 to Jan 1, 2026
Biomea Fusion Inc.Phase 1 NCT05918692 Registry history of NCT05918692 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Study completion moved earlier from Jul 30, 2028 to Dec 31, 2027
French Innovative Leukemia OrganisationNot specified NCT04411043 Registry history of NCT04411043 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Primary completion date changed from estimate of Dec 2026 to May 29, 2026
AbbVieNot specified NCT05317494 Registry history of NCT05317494 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Study completion date changed from estimate of Mar 31, 2026 to Feb 28, 2026
Bristol-Myers SquibbNot specified NCT07458542 Registry history of NCT07458542 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Primary completion date changed from estimate of Nov 2026 to Jul 21, 2026
AbbVieNot specified NCT06058741 Registry history of NCT06058741 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Final enrollment: 8 participants (planned 18)
Memorial Sloan Kettering Cancer CenterPhase 1 NCT05756777 Registry history of NCT05756777 on ClinicalTrials.gov (opens the registry)
Trial completed
Samara State Medical UniversityNot specified NCT05682924 Registry history of NCT05682924 on ClinicalTrials.gov (opens the registry)
Trial completed
Samara State Medical UniversityNot applicable NCT05703126 Registry history of NCT05703126 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Primary completion date changed from estimate of Dec 31, 2027 to Aug 4, 2026
Arbeitsgemeinschaft medikamentoese TumortherapieNot specified NCT06250465 Registry history of NCT06250465 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Jan 31, 2027 to Apr 30, 2027
Acerta Pharma BVPhase 3 NCT03836261 Registry history of NCT03836261 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Sep 2026 to Nov 2026
Miltenyi Biomedicine GmbHPhase 1 NCT03853616 Registry history of NCT03853616 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Nov 2026 to Mar 2027
Also in this update: Study completion pushed from Nov 2029 to Mar 2030
BeOne MedicinesPhase 1/2 NCT05006716 Registry history of NCT05006716 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Final enrollment: 34 participants (planned 80)
Fundacion CRIS de Investigación para Vencer el CáncerPhase 2 NCT04160546 Registry history of NCT04160546 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Study completion pushed from Feb 22, 2027 to Mar 30, 2031; Primary completion date changed from estimate of Feb 22, 2027 to Sep 23, 2026
Mayo ClinicPhase 2 NCT05388006 Registry history of NCT05388006 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Primary completion date changed from estimate of Jul 7, 2026 to May 27, 2026
Institut Paoli-CalmettesPhase 2 NCT01985061 Registry history of NCT01985061 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Massachusetts General HospitalPhase 2 NCT04560322 Registry history of NCT04560322 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Primary completion pushed from Sep 2026 to Jan 2027
Weill Medical College of Cornell UniversityPhase 2 NCT04679012 Registry history of NCT04679012 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Enrollment reduced: 77 → 60 participants; Primary completion date changed from estimate of Dec 1, 2026 to Jul 31, 2026
The First Affiliated Hospital of Soochow UniversityPhase 2 NCT06379360 Registry history of NCT06379360 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Study completion pushed from Nov 1, 2026 to Feb 1, 2027; Primary completion date changed from estimate of Nov 1, 2026 to Aug 31, 2026
Donald ArnoldNot applicable NCT06947044 Registry history of NCT06947044 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Aug 31, 2026 to Dec 31, 2026
Northside Hospital, Inc.Phase 2 NCT05909059 Registry history of NCT05909059 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Nov 1, 2026 to Feb 1, 2027
Also in this update: Study completion pushed from Dec 1, 2026 to Jun 1, 2027
Northside Hospital, Inc.Phase 2 NCT05519579 Registry history of NCT05519579 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Oct 16, 2026 to Mar 30, 2027
Novartis PharmaceuticalsNot specified NCT07454850 Registry history of NCT07454850 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Final enrollment: 27 participants (planned 34)
Karamanoğlu Mehmetbey UniversityNot applicable NCT06794762 Registry history of NCT06794762 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 23 → 27 locations
Merck Sharp & Dohme LLCPhase 2/3 NCT07570173 Registry history of NCT07570173 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Oct 31, 2026 to Nov 30, 2026
Also in this update: Study completion pushed from Nov 1, 2026 to Jul 1, 2027
University of MiamiNot applicable NCT05745285 Registry history of NCT05745285 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Sep 2026 to Dec 2026
Stanford UniversityPhase 1 NCT05188170 Registry history of NCT05188170 on ClinicalTrials.gov (opens the registry)
Trial completed
St. Jude Children's Research HospitalNot applicable NCT05550948 Registry history of NCT05550948 on ClinicalTrials.gov (opens the registry)
Sponsor refiled this as recruiting (was completed)
British Columbia Cancer AgencyNot specified NCT06224309 Registry history of NCT06224309 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 92 → 99 locations
And 4 more changes in the last 30 days
Merck Sharp & Dohme LLCPhase 3 NCT05947851 Registry history of NCT05947851 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Dec 2026 to Mar 2027
Also in this update: Study completion pushed from Jul 2027 to Sep 2027
Benjamin TomlinsonPhase 1/2 NCT06129734 Registry history of NCT06129734 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 122 → 136 locations
And 1 more change in the last 30 days
Kura Oncology, Inc.Phase 3 NCT07007312 Registry history of NCT07007312 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 203 → 206 locations
Merck Sharp & Dohme LLCPhase 3 NCT06136559 Registry history of NCT06136559 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 30 → 34 locations
Novartis PharmaceuticalsPhase 2 NCT07354074 Registry history of NCT07354074 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Sep 4, 2026 to Dec 4, 2026
Also in this update: Study completion pushed from Dec 4, 2026 to Jun 4, 2027
Beth Israel Deaconess Medical CenterPhase 2 NCT03059485 Registry history of NCT03059485 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 280 → 285 locations
National Cancer Institute (NCI)Phase 2 NCT03739814 Registry history of NCT03739814 on ClinicalTrials.gov (opens the registry)
Enrollment increased: 10 → 12 participants
PfizerNot specified NCT06476665 Registry history of NCT06476665 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 37 → 40 locations
And 3 more changes in the last 30 days
National Cancer Institute (NCI)Phase 2 NCT07437950 Registry history of NCT07437950 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 28 → 33 locations
Quetzal TherapeuticsPhase 3 NCT07504458 Registry history of NCT07504458 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Dec 31, 2027 to Jun 22, 2028
Also in this update: Enrollment increased: 18 → 20 participants
City of Hope Medical CenterNot specified NCT07613385 Registry history of NCT07613385 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 214 → 217 locations
BeOne MedicinesPhase 3 NCT06973187 Registry history of NCT06973187 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 109 → 149 locations
Syndax PharmaceuticalsPhase 3 NCT07211958 Registry history of NCT07211958 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 262 → 266 locations
Janssen Research & Development, LLCPhase 3 NCT06852222 Registry history of NCT06852222 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 32 → 35 locations
AbbViePhase 2/3 NCT07581002 Registry history of NCT07581002 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 11 → 14 locations
Autolus LimitedPhase 1 NCT06173518 Registry history of NCT06173518 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 1 → 4 locations
Charm TherapeuticsPhase 1 NCT07751991 Registry history of NCT07751991 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 17 → 20 locations
BeOne MedicinesPhase 1/2 NCT06697184 Registry history of NCT06697184 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 10 → 13 locations
Tempus AINot specified NCT07154823 Registry history of NCT07154823 on ClinicalTrials.gov (opens the registry)
Trial sites reduced: 23 → 20 locations
AstraZenecaPhase 1 NCT05877599 Registry history of NCT05877599 on ClinicalTrials.gov (opens the registry)
Enrollment increased: 52 → 72 participants
M.D. Anderson Cancer CenterPhase 2 NCT03629171 Registry history of NCT03629171 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 22 → 26 locations
Blueprint Medicines CorporationNot specified NCT07143669 Registry history of NCT07143669 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 65 → 69 locations
Novartis PharmaceuticalsNot specified NCT07549516 Registry history of NCT07549516 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 68 → 71 locations
And 1 more change in the last 30 days
National Cancer Institute (NCI)Phase 2 NCT06917911 Registry history of NCT06917911 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 11 → 16 locations
SWOG Cancer Research NetworkPhase 2 NCT06773936 Registry history of NCT06773936 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 2 → 7 locations
National Cancer Institute (NCI)Phase 2 NCT07605416 Registry history of NCT07605416 on ClinicalTrials.gov (opens the registry)
Study completion moved earlier from Sep 15, 2028 to Aug 10, 2028
Also in this update: Primary completion moved earlier from Feb 11, 2028 to Jan 6, 2028
AstraZenecaPhase 1/2 NCT06137118 Registry history of NCT06137118 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 82 → 97 locations
Stichting Hemato-Oncologie voor Volwassenen NederlandPhase 3 NCT07223814 Registry history of NCT07223814 on ClinicalTrials.gov (opens the registry)
Start date changed from estimate of Oct 16, 2026 to Sep 16, 2026
And 1 more change in the last 30 days
Amphista Therapeutics LtdPhase 1 NCT07723703 Registry history of NCT07723703 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 210 → 224 locations
Alliance for Clinical Trials in OncologyPhase 3 NCT07321652 Registry history of NCT07321652 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 24 → 29 locations
Stichting Hemato-Oncologie voor Volwassenen NederlandPhase 1/2 NCT05791409 Registry history of NCT05791409 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 15 → 20 locations
PETHEMA FoundationPhase 2 NCT07507760 Registry history of NCT07507760 on ClinicalTrials.gov (opens the registry)
Primary completion date changed from estimate of Jan 30, 2027 to Aug 11, 2026
Bristol-Myers SquibbPhase 1/2 NCT06035497 Registry history of NCT06035497 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Dec 31, 2026 to Dec 31, 2028
Taiho Oncology, Inc.Phase 1/2 NCT04657081 Registry history of NCT04657081 on ClinicalTrials.gov (opens the registry)
Start date pushed from Sep 25, 2026 to Oct 9, 2026
Merck Sharp & Dohme LLCPhase 2 NCT07709000 Registry history of NCT07709000 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 3 → 6 locations
Resonance, Inc.Not specified NCT07632014 Registry history of NCT07632014 on ClinicalTrials.gov (opens the registry)
Study completion moved earlier from Nov 1, 2031 to Oct 1, 2031
Novartis PharmaceuticalsPhase 1/2 NCT04925479 Registry history of NCT04925479 on ClinicalTrials.gov (opens the registry)
Primary completion date changed from estimate of Nov 16, 2026 to Sep 2, 2026
Janssen Research & Development, LLCPhase 1 NCT06618001 Registry history of NCT06618001 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Oct 30, 2028 to Dec 29, 2028
Janssen Research & Development, LLCPhase 1 NCT06788509 Registry history of NCT06788509 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Mar 3, 2027 to Jun 30, 2027
Janssen Research & Development, LLCPhase 1 NCT05453903 Registry history of NCT05453903 on ClinicalTrials.gov (opens the registry)
Start date changed from estimate of Oct 15, 2026 to Oct 13, 2026
Fred Hutchinson Cancer CenterNot applicable NCT07094750 Registry history of NCT07094750 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Aug 14, 2027 to Sep 30, 2034
Children's Oncology GroupPhase 3 NCT03007147 Registry history of NCT03007147 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Oct 29, 2027 to Nov 30, 2027
Janssen Cilag S.A.S.Not specified NCT06299540 Registry history of NCT06299540 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Dec 31, 2026 to Feb 1, 2027
OHSU Knight Cancer InstitutePhase 1 NCT05396859 Registry history of NCT05396859 on ClinicalTrials.gov (opens the registry)
Study completion moved earlier from Oct 2028 to Aug 2028
Also in this update: Primary completion moved earlier from Oct 2027 to Aug 2027
University of Michigan Rogel Cancer CenterPhase 1 NCT07532525 Registry history of NCT07532525 on ClinicalTrials.gov (opens the registry)
Interventions modified
Also in this update: Trial arms changed: 39 → 41; and 1 more change in the last 30 days
National Cancer Institute (NCI)Phase 2 NCT05564390 Registry history of NCT05564390 on ClinicalTrials.gov (opens the registry)
Study completion moved earlier from Oct 2028 to Feb 2028
Northwell HealthPhase 2 NCT07163793 Registry history of NCT07163793 on ClinicalTrials.gov (opens the registry)
Interventions modified
Mayo ClinicPhase 2 NCT03418038 Registry history of NCT03418038 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Jun 2027 to Jun 2040
Also in this update: Primary completion date changed from estimate of Jun 2027 to Jul 17, 2025
Stanford UniversityPhase 1Unusual date NCT05993949 Registry history of NCT05993949 on ClinicalTrials.gov (opens the registry)
Study completion pushed from May 23, 2026 to May 23, 2027
Baylor College of MedicineNot applicable NCT05236764 Registry history of NCT05236764 on ClinicalTrials.gov (opens the registry)
Start date pushed from Sep 30, 2026 to Oct 1, 2026
Liping DouPhase 1 NCT07841002 Registry history of NCT07841002 on ClinicalTrials.gov (opens the registry)
Study completion pushed from May 31, 2026 to Dec 31, 2026
Massachusetts General HospitalPhase 1 NCT03770429 Registry history of NCT03770429 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Aug 31, 2026 to Dec 31, 2026
Beth Israel Deaconess Medical CenterPhase 1 NCT03679650 Registry history of NCT03679650 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Sep 2026 to Sep 2027
H. Lee Moffitt Cancer Center and Research InstitutePhase 1 NCT05015426 Registry history of NCT05015426 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Jul 29, 2026 to Jun 28, 2027
City of Hope Medical CenterPhase 1 NCT03560752 Registry history of NCT03560752 on ClinicalTrials.gov (opens the registry)
Interventions modified
Also in this update: Trial arms changed: 3 → 4
Washington University School of MedicinePhase 1 NCT05044039 Registry history of NCT05044039 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Dec 1, 2039 to Dec 1, 2040
Also in this update: Primary completion date changed from estimate of Sep 1, 2025 to Dec 11, 2025
Benjamin TomlinsonPhase 1 NCT04732845 Registry history of NCT04732845 on ClinicalTrials.gov (opens the registry)
Study completion moved earlier from Jun 2028 to Mar 2028
Fundación para la Investigación Biosanitaria del Principado de AsturiasNot applicable NCT07597590 Registry history of NCT07597590 on ClinicalTrials.gov (opens the registry)
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
Delta-Fly Pharma, Inc.Phase 1/2 NCT06382168 Registry history of NCT06382168 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
FamiCordTxPhase 1 NCT06593145 Registry history of NCT06593145 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
Epigenetix, Inc.Phase 1 NCT05488548 Registry history of NCT05488548 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Jan 2023); last known: Recruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.Phase 1 NCT05367700 Registry history of NCT05367700 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Active, Not Recruiting
Baseline Study LLCNot specified NCT03154346 Registry history of NCT03154346 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
ETH ZurichPhase 2 NCT06138990 Registry history of NCT06138990 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Oct 2023); last known: Not Yet Recruiting
Sichuan UniversityPhase 2 NCT06075238 Registry history of NCT06075238 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
The University of Hong KongPhase 2 NCT04687176 Registry history of NCT04687176 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Not Yet Recruiting
Institute of Hematology & Blood Diseases Hospital, ChinaNot applicable NCT06758726 Registry history of NCT06758726 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Not Yet Recruiting
Institute of Hematology & Blood Diseases Hospital, ChinaNot applicable NCT06658938 Registry history of NCT06658938 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since May 2024); last known: Recruiting
The First Affiliated Hospital with Nanjing Medical UniversityNot applicable NCT05950997 Registry history of NCT05950997 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Aug 2021); last known: Recruiting
University Hospital, BrestNot specified NCT05009537 Registry history of NCT05009537 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Active, Not Recruiting
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSNot specified NCT03789981 Registry history of NCT03789981 on ClinicalTrials.gov (opens the registry)
Changed
Registry verification sweep
Changed
Registry marked status Unknown (sponsor has not verified the record since Aug 2021); last known: Not Yet Recruiting
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Phase 1/2 NCT05055791 Registry history of NCT05055791 on ClinicalTrials.gov (opens the registry)
Changed
| First posted | Trial | Sponsor | Phase |
|---|---|---|---|
| 2026-10-14 | NCT07872709 Oral Tetrahydrouridine-Decitabine in Patients With Advanced Myeloproliferative Neoplasms | John Mascarenhas new | Phase 2 |
| 2026-10-14 | NCT07874100 This Study Aims to Improve the Stratification of Patients With Acute Myeloid Leukemia to… | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico new | |
| 2026-10-09 | NCT07867600 Low Dose Induction for Pediatric Acute Myeloid Leukemia Patients | Azza Shibl Sayed new | |
| 2026-10-06 | NCT07861477 Murottal as Adjunctive Intervention in Pediatric | Universitas Airlangga new | |
| 2026-09-10 | NCT07814170 A Manualised Post-Traumatic Growth Intervention For People With Hematological Cancers In… | University of West Attica new | |
| 2026-09-09 | NCT07809906 Study of ORM-1153 in Acute Myeloid Leukemia (AML) With CD123 Expression | Orum Therapeutics USA, Inc. new | Phase 1 |
| 2026-09-04 | NCT07804901 Asciminib Frontline Risk Adapted | Prof. Dr. med. Andreas Hochhaus new | Phase 2 |
| 2026-09-04 | NCT07805096 Efficacy of a Smart Holistic Health Care Platform Intervention on Cancer Children and… | National Defense Medical University, Taiwan new | |
| 2026-09-03 | NCT07802015 Home-based Intravenous Cytarabine Treatment for Acute Myeloid Leukemia: a National Danish… | Zealand University Hospital new | |
| 2026-08-19 | NCT07774390 Ibrutinib Plus Venetoclax Long-Term Outcomes in CLL | European Research Initiative on CLL new |
| Early Phase 1 | 76 | |
| Phase 1 | 494 | |
| Phase 1/2 | 292 | |
| Phase 2 | 652 | |
| Phase 2/3 | 52 | |
| Phase 3 | 167 | |
| Phase 4 | 26 |
M.D. Anderson Cancer Center (121) · National Cancer Institute (NCI) (95) · Institute of Hematology & Blood Diseases Hospital, China (91) · City of Hope Medical Center (59) · The First Affiliated Hospital of Soochow University (55) · Memorial Sloan Kettering Cancer Center (46) · Dana-Farber Cancer Institute (37) · St. Jude Children's Research Hospital (37) · Peking University People's Hospital (31) · Novartis Pharmaceuticals (27)